This visual abstract depicts how Wei et al. utilize single -
cell phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.
The technology the team used is called single -
cell phosphoproteomics.
In the paper, the researchers also described that single -
cell phosphoproteomics could be used to study how melanoma cells develop resistance to a class of drugs called BRAF inhibitors.
Not exact matches
In the new paper, Kajimura's team collaborated with the laboratory of Yasushi Ishihama, PhD, of the University of Kyoto, Japan, to search for differences in how white and brown fat
cells respond to the cold using a technique called
phosphoproteomics.
Applying these methods to prostate cancer
cell lines, the researchers found that accurate predictions of drug sensitivity could be achieved using either genomics data or
phosphoproteomics data alone.
Her interests centre on developing methods for quantitative proteomics,
phosphoproteomics and methods for tracking changes in sub-cellular localization of the proteome in response to
cell signalling events.
Proteomics and
phosphoproteomics analyses in melanoma
cells identified CDK2 as a driver of resistance to both BRAF and Hsp90 inhibitors.